# Vertex Pharmaceuticals Incorporated  Share Price Target ‘$465.33’, now 12.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-share-price-target-465.33-now-12.9-upside-potential/4121148706
- Published: 2024-03-22T14:04:04+00:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** which can be found using ticker (VRTX) have
now 24 market analysts covering the stock. The analyst consensus now points to a
rating of ‘buy’. The target price High/Low ranges between $574.00 and $325.00 calculating
the mean target share price we have $465.33. (at the time of writing). Given that
the stocks previous close was at $412.11 and the analysts are correct then there
would likely be a percentage uptick in value of 12.9%. It’s also worth noting that
there is a 50 day moving average of $424.15 while the 200 day moving average is 
$375.89. The company has a market capitalization of 107.38B. The stock price is 
currently at: $415.71 USD

 The potential market cap would be $121,248,459,853 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 29.93, revenue per share of $38.30
and a 13.17% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on: